Skip to main content
. Author manuscript; available in PMC: 2008 Aug 1.
Published in final edited form as: Oncogene. 2007 Dec 10;27(22):3081–3090. doi: 10.1038/sj.onc.1210977

Figure 1.

Figure 1

Activity of E1A CR2-deleted adenoviral vectors in ovarian cancer. (a) IGROV1 and OVCAR4 cells were infected with dl922-947, dlCR2 and dlCR2 tSmac (MOI 0.001-10000 plaque-forming unit (PFU) per cell). Cell viability was assessed 120 h later. Results are presented as percentage cell survival compared to mock-infected cells (mean±s.d. n=3). IC50 results are presented in tabular form. (b) IGROV1 cells were infected with dl922-947, dlCR2, dlCR2 tSmac and Ad LM-X (all MOI 10), mock-infected or incubated with cisplatin (10 μm) in triplicate. After 72 h, caspase activation was measured using PhiPhi Lux-G1D2. (c) Following infection with dl922-947 (MOI 0.001-1000), IGROV1 cells were treated with zVAD-fmk (0-25 μm). Cell viability was assessed 144 h later. (d) IGROV1 cells were treated with cisplatin (1 and 10 μm) with and without 25 μm zVAD-fmk. Cell survival was assessed after 72 h by MTT assay. ***P<0.001. (e) IGROV1 cells were harvested up to 120 h following infection with dlCR2 (MOI 10). About 20 μg of protein was separated on sodium dodecyl sulphate (SDS)-PAGE gels and analysed for expression of caspase-3, E1A and PARP by immunoblot.